BARCELONA: Almirall, S.A. (ALM), a global biopharmaceutical company specializing in medical dermatology, reported a 12.7% increase in net sales for the first half of 2025, reaching €560.5 million, up from €497.2 million in the same period last year. EBITDA rose 16.6% to €121.8 million, bolstered by robust revenue and a gross profit margin of 65.5%.
The company’s dermatology segment in Europe delivered strong results, with net sales surging 24.2% year-on-year to €289.5 million. Almirall reaffirmed its full-year guidance for 2025, projecting net sales growth of 10–13% and EBITDA between €220 million and €240 million.
Ebglyss®, indicated for moderate-to-severe atopic dermatitis, generated €45 million in H1 sales, more than quadrupling year-on-year. Sales in Q2 reached €25 million, making it Almirall’s second-best selling product just 18 months post-launch. The treatment is now reimbursed in 14 countries, with additional rollouts planned in Portugal and Ireland.
Ilumetri®, for moderate-to-severe psoriasis, continued its upward trajectory with €58 million in Q2 sales, aided by strong demand for its 200mg formulation. The brand is on track to surpass €300 million in peak sales.
R&D investment grew 27% in H1 2025, accounting for 12.8% of net sales. Highlights include advancement of Almirall’s anti-IL-1RAP monoclonal antibody, with Phase I results showing low immunogenicity and favorable safety. A Phase II study in Hidradenitis suppurativa is slated for later this year.
The company also expanded its collaboration with Simcere to accelerate multispecific antibody development, enhancing access to innovative R&D in China.
Chairman and CEO Carlos Gallardo said, “Our biologics portfolio continues to roll out successfully across Europe, reaffirming our long-term ambition to lead in medical dermatology and bring impactful treatments to more patients.”